Pediatric CKD and cardivascular disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 3, 2014, Pages 177-184

  Safder, Osama ^a,b   Al Sharif, Shafiqa ^b   Kari, Jameela A ^a,b  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Atherosclerosis; Cardiovascular disease; Children; Chronic kidney disease; Renal failure; Risk factors

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HOMOCYSTEINE; INSULIN; STEROID; TACROLIMUS; VITAMIN D;

ANEMIA; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BONE DISEASE; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROPATHY; OXIDATIVE STRESS; PEDIATRICS; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SMOKING; SYSTEMATIC REVIEW (TOPIC); ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; CHRONIC KIDNEY FAILURE; COMPLICATION; PATHOLOGY; VASCULAR ENDOTHELIUM;

ADOLESCENT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHILD; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84924158813     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140401112335     Document Type: Article

References (52)

1. McGill, H.C.; McMahan, C.A.; Zieske, A.W.; Tracy, R.E.; Malcom, G.T.; Herderick, E.E.; Strong, J.P. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation, 2000, 102(4), 374-9.
2. Strong, J.P.; Malcom, G.T.; McMahan, C.A.; Tracy, R.E.; Newman, W.P.; 3rd, Herderick, E.E.; Cornhill, JF. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA, 1999, 281(8), 727-35.
3. Garg, A.X.; Clark, W.F.; Haynes, R.B.; House, A.A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int., 2002, 61(4), 1486-94.
4. Moody, W.E.; Edwards, N.C.; Chue, C.D.; Ferro, C.J.; Townend, J.N. Arterial disease in chronic kidney disease. Heart, 2013, 99(6), 365-72.
5. Chavers, B.M.; Li, S.; Collins, A.J.; Herzog, C.A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int., 2002, 62(2),648-53.
6. Baigent, C.; Burbury, K.; Wheeler, D. Premature cardiovascular disease in chronic renal failure. Lancet, 2000, 356,147-152.
7. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. Rockville, MD: Agency for Healthcare Research and Quality. Available at: www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guidesreviews- andreports/? pageaction=displayproduct&productid=318[accessed May 19, 2013].
8. Litwin, M.; Wuhl, E.; Jourdan, C.; Trelewicz, J.; Niemirska, A.; Fahr, K.; Jobs, K.; Grenda, R.; Wawer, Z.T.; Rajszys, P.; Troger, J.; Mehls, O.; Schaefer, F. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J. Am. Soc. Nephrol., 2005, 16(5), 1494-500.
9. Covic, A.; Mardare, N.; Gusbeth-Tatomir, P.; Brumaru, O.; Gavrilovici, C.; Munteanu, M.; Prisada, O.; Goldsmith, D.J. Increased arterial stiffness in children on haemodialysis. Nephrol. Dial Transplant., 2006, 21(3): 729-35.
10. Kari, J.A.; Donald, A.E.; Vallance, D.T.; Bruckdorfer, K.R.; Leone, A.; Mullen, M.J.; Bunce, T.; Dorado, B.; Deanfield, J.E.; Rees L. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int., 1997, 52(2), 468- 72.
11. Dursun, I.; Poyrazoglu, H.M.; Gunduz, Z.; Ulger, H.; Yykylmaz, A.; Dusunsel, R.; Patyroglu, T.; Gurgoze, M. The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol. Dial Transplant., 2009, 24(8), 2511-8.
12. Ardissino, G.; Dacco, V.; Testa, S.; Bonaudo, R.; Claris-Appiani, A.; Taioli, E.; Marra, G.; Edefonti, A.; Sereni, F.; ItalKid Project. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics, 2003, 111, e382.
13. Olowu, W.A.; Adefehinti, O.; Aladekomo, T.A. Epidemiology and clinicopathologic outcome of pediatric chronic kidney disease in Nigeria, a single cenetr study. Arab. J. Nephrol. Transplant., 2013, 6(2):105-14.
14. Harris, J.; Robert, E.; Kallen, B. Epidemiologic characteristics of kidney malformations. Eur. J. Epidemiol., 2000, 16(11), 985.
15. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 Annual Report. Available at: https://web.emmes. com/study/ped/announce.htm[accessed May 21, 2013].
16. Hoy, W.E. Renal disease in Australian aboriginals. Med. J. Aust., 1996, 165,126.
17. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics, 2004, 114(2) 4th Report: 555-76.
18. Lande, M.B.; Carson, N.L.; Roy, J.; Meagher, C.C. Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension, 2006, 48(1): 40-4.
19. Brady, T.M.; Fivush, B.; Flynn, J.T.; Parekh, R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J. Pediatr., 2008, 152(1), 73-8, 78.
20. An, H.R.; Park, S.; Yoo, T.H.; Kang, S.W.; Ryu, J.H.; Lee, Y.K.; Yu, M.; Ryu, D.R.; Kim, S.J.; Kang, D.H.; Choi, K.B. Non-dipper status and left ventricular hypertrophy as predictors of incident chronic kidney disease. J. Korean Med. Sci., 2011, 26(9), 1185-90.
21. Urbina, E.; Alpert, B.; Flynn, J.; Hayman, L.; Harshfield, G.A.; Jacobson, M.; Mahoney, L.; McCrindle, B.; Mietus-Snyder, M.; Steinberger, J.; Daniels, S.; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension, 2008, 52(3), 433-51.
22. Wuhl, E.; Trivelli, A.; Picca, S.; Litwin, M.; Peco-Antic, A.; Zurowska, A.; Testa, S.; Jankauskiene, A.; Emre, S.; Caldas- Afonso, A.; Anarat, A.; Niaudet, P.; Mir, S.; Bakkaloglu, A.; Enke, B.; Montini, G.; Wingen, A.M.; Sallay, P.; Jeck, N.; Berg, U.; Caliskan, S.; Wygoda, S.; Hohbach-Hohenfellner, K.; Dusek, J.; Urasinski, T.; Arbeiter, K.; Neuhaus, T.; Gellermann, J.; Drozdz, D.; Fischbach, M.; Moller, K.; Wigger, M.; Peruzzi, L.; Mehls, O.; Schaefer, F. Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med., 2009, 361(17), 1639-50.
23. Yasuda, T.; Endoh, M.; Suzuki, D.; Yoshimura, A.; Ideura, T.; Tamura, K.; Kamata, K.; Toya, Y.; Umemura, S.; Kimura, K.; KVT Study Group. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens. Res., 2013, 36(3), 240-6.
24. Kari, J.A.; Shaw, V.; Vallance, D.T.; Rees, L. Effect of enteral feeding on lipid subfractions in children with chronic renal failure. Pediatr. Nephrol., 1998, 12(5), 401-4.
25. Singh, A.K.; Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl. J. Med., 2006, 355(20), 2085-98.
26. Pfeffer, M.A.; Burdmann, E.A.; Chen, C.Y.; Cooper, M.E.; de Zeeuw, D.; Eckardt, K.U.; Feyzi, J.M.; Ivanovich, P.; Kewalramani, R.; Levey, A.S.; Lewis, E.F.; McGill, J.B.; McMurray, J.J.; Parfrey, P.; Parving, H.H.; Remuzzi, G.; Singh, A.K.; Solomon, S.D.; Toto, R.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med., 2009, 361(21), 2019-32.
27. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis., 2007, 50(3), 471- 530.
28. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L.; Elashoff, R.M.; Salusky, I.B. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med., 2000, 342, 1478-83.
29. Russo, D.; Miranda, I.; Ruocco, C.; Battaglia, Y.; Buonanno, E.; Manzi, S.; Russo, L.; Scafarto, A.; Andreucci, V.E. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int., 2007, 72, 1255-61.
30. Goodman, W.G.; London, G.; Amann, K.; Block, G.A.; Giachelli, C.; Hruska, K.A.; Ketteler, M.; Levin, A.; Massy, Z.; McCarron, D.A.; Raggi, P.; Shanahan, C.M.; Yorioka, N.; Vascular Calcification Work Group. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis., 2004, 43(3), 572-9.
31. Spence, L.A.; Weaver, C.M. Calcium intake, vascular calcification, and vascular disease. Nutr. Rev., 2013, 71(1),15-22.
32. Qunibi, W.; Moustafa, M.; Muenz, L.R.; He, D.Y.; Kessler, P.D.; Diaz-Buxo, J.A.; Budoff, M.; CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am. J. Kidney Dis., 2008, 51(6), 952-65.
33. Block, G.A.; Spiegel, D.M.; Ehrlich, J.; Mehta, R.; Lindbergh, J.; Dreisbach, A.; Raggi, P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int., 2005, 68(4), 1815-24.
34. Chertow, G.M.; Burke, S.K.; Raggi, P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int., 2002, 62(1), 245-52.
35. Suki, W.N.; Zabaneh, .R; Cangiano, J.L.; Reed, J.; Fischer, D.; Garrett, L.; Ling, B.N.; Chasan-Taber, S.; Dillon, M.A.; Blair, A.T.; Burke, S.K. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int., 2007, 72(9), 1130-7.
36. Lishmanov, A.; Dorairajan, S.; Pak, Y.; Chaudhary, K.; Chockalingam, A. Treatment of 25-OH Vitamin D Deficiency in Older Men With Chronic Kidney Disease Stages 3 and 4 Is Associated With Reduction in Cardiovascular Events. Am. J. Therz., 2013, 20(5), 480-6.
37. Shroff, R.; Egerton, M.; Bridel, M.; Shah, V.; Donald, A.E.; Cole, T.J.; Hiorns, M.P.; Deanfield, J.E.; Rees, L. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol., 2008, 19(6), 1239-46.
38. Jean, G.; Bresson, E.; Lorriaux, C.; Mayor, B.; Hurot, J.M.; Deleaval, P.; Chazot, C. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long hour hemodialysis patients. Nephron. Clin. Pract., 2012, 120(3), c132-c138.
39. Unsal, A.; Kose, B.S.; Koc, Y.; Basturk, T.; Sakaci, T.; Ahbap, E.; Sinangil, A. Relationship of Fibroblast Growth Factor 23 with Left Ventricle Mass Index and Coronary Calcificaton in Chronic Renal Disease. Kidney Blood Press Res., 2012, 36(1), 55-64.
40. Humphrey, L.L.; Fu, R.; Rogers, K.; Freeman, M.; Helfand, M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin. Proc. 2008, 83(11), 1203-12.
41. Albert, C.M.; Cook, N.R.; Gaziano, J.M.; Zaharris, E.; MacFadyen, J.; Danielson, E.; Buring, J.E.; Manson, J.E . Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA, 2008, 299(17), 2027-36.
42. Qin, X.; Xu, M.; Zhang, Y.; Li, J.; Xu, X.; Wang, X.; Xu, X.; Huo, Y. Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis, 2012, 222(2), 307-13.
43. Eschwege, E.; Richard, J.L.; Thibult, N.; Ducimetiere, P.; Warnet, J.M.; Claude, J.R.; Rosselin, G.E. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm. Metab. Res. Suppl., 1985, 15, 41-6.
44. Weinrauch, L.A.; Healy, R.W.; Leland, O.S.; Jr, Goldstein, H.H.; Libertino, J.A.; Takacs, F.J.; Bradley, R.F.; Gleason, R.E.; D'Elia, J.A. Decreased insulin requirement in acute renal failure in diabetic nephropathy. Arch. Intern. Med., 1978, 138(3), 399-402.
45. Selvin, E.; Marinopoulos, S.; Berkenblit ,G.; Rami, T.; Brancati, F.L.; Powe, N.R.; Golden, S.H. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med., 2004, 141(6), 421-31.
46. Aiello, L.M. Perspectives on diabetic retinopathy. Am. J. Ophthalmol., 2003, 136(1), 122-35.
47. Partanen, J.; Niskanen, L.; Lehtinen, J.; Mervaala, E.; Siitonen, O.; Uusitupa, M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 1995, 333(2), 89-94.
48. Jee, S.H.; Suh, I.; Kim, I.S.; Appel, L.J. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. JAMA, 1999, 282(22), 2149-55.
49. Steenland, K.; Thun, M.; Lally, C.; Heath, C.; Jr. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation, 1996, 94(4), 622-8.
50. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. The metabolic syndrome. Endocr. Rev., 2008, 29, 777-822.
51. Naesens, M.; Kuypers, D.R.J.; Sarwal, M. Calcineurin Inhibitor Nephrotoxicity. Clin. J. Am. Soc. Nephrol., 2009, 4(2), 481-508.
52. Bugliani, M.; Masini, M.; Liechti, R.; Marselli, L.; Xenarios, I.; Boggi, U.; Filipponi, F.; Masiello, P.; Marchetti, P. The direct effects of tacrolimus and cyclosporin A on isolated human islets: A functional, survival and gene expression study. Islets, 2009, 1(2), 106-10.